EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access

Evaluation of the Safety, Genetic Stability, and Immunogenicity of an Attenuated Shigella Live Vector Expressing Enterotoxigenic Escherichia coli Antigens, Vaccine Strain CVD 1208S-122

Wilbur H Chen iD, Eileen M Barry iD, Franklin R Toapanta iD, Marcela F Pasetti iD, Marcelo B Sztein iD, Jasnehta Permala-Booth iD, Sharon M Tennant iD, Justin R Ortiz iD, Constance Thomas, Megan McGilvray iD, Lynnee Roane iD, Reva Datar iD und 2 weitere

The Journal of Infectious Diseases · 2026

DOI: 10.1093/infdis/jiag220 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Wilbur H Chen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Antigens, Bacterial, Enterotoxigenic Escherichia coli, Escherichia coli Infections, Escherichia coli Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There are no licensed vaccines to protect against Shigella or enterotoxigenic Escherichia coli (ETEC), yet they are among the most common causes of bacterial diarrhea. We engineered an attenuated Shigella flexneri 2a expressing colonization factor antigen 1 (CFA/I) and heat-labile enterotoxin B subunit (LTB) from ETEC and conducted a first-in-human randomized-controlled trial of ascending doses of the vaccine (CVD 1208S-122).

Methods

Dose-escalating cohorts received a single oral dose of 108–1010 colony-forming units (CFU) of CVD 1208S-122 or placebo. A fourth cohort received 1 or 2 oral doses of 108 CFU CVD 1208S-122 or placebo. We measured the safety and clinical acceptability of the vaccine, genetic stability of fecally shed vaccine organisms, and immune responses elicited.

Results

The 108 CFU doses were well tolerated (100%, 6/6). One recipient of 109 CFU (20%, 1/5) manifested diarrhea and 4 individuals who ingested 1010 CFU had either fever or diarrheal reactogenicity (67%, 4/6). Fecal shed vaccine organisms were genetically stable. Responses were observed to the lipopolysaccharide (LPS) and invasion plasmid antigen B (IpaB) of Shigella and CFA/I fimbriae and LTB of ETEC in serum, among antibody secreting cells, antibody in lymphocyte supernatant, and fecal samples. Serum antibodies exhibited Shigella bactericidal activity and inhibition of ETEC adherence in vitro.

Conclusions

This study demonstrates safety with low-dose but unacceptable reactogenicity following highest-dose ingestion, genetic stability of all recovered fecal isolates, and immunogenicity of a prototype combined monovalent Shigella-ETEC vaccine. These results encourage expansion to a multivalent formulation to elicit broader protection against the most prevalent Shigella serotypes and ETEC CFA types that cause diarrheal disease. Clinical Trials Registration NCT04634513.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, BacterialEnterotoxigenic Escherichia coliEscherichia coli InfectionsEscherichia coli VaccinesShigella flexneriShigella VaccinesAdolescentAdultFemaleHumansMaleYoung AdultAntibodies, BacterialBacterial ToxinsDiarrheaDysentery, BacillaryEnterotoxinsEscherichia coli ProteinsFecesFimbriae ProteinsGenetic VectorsImmunogenicity, VaccineVaccines, Attenuated

Stichwörter der Autor:innen

Shigella; ETECdiarrheaimmunityvaccine

Substanzen

Antibodies, BacterialAntigens, BacterialBacterial Toxinscolonization factor antigensEnterotoxinsEscherichia coli ProteinsEscherichia coli VaccinesFimbriae Proteinsheat-labile enterotoxin, E coliShigella Vaccines

Autor:innen und Institutionen

  • Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Program in Oncology, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.
  • Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Division of Biostatistics and Bioinformatics, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Wilbur H Chen, Eileen M Barry, Franklin R Toapanta, Marcela F Pasetti, Marcelo B Sztein, Jasnehta Permala-Booth, Sharon M Tennant, Justin R Ortiz, Megan McGilvray, Lynnee Roane, Reva Datar, Myron M Levine

Förderung

  • NIAID NIH HHS
  • NCI NIH HHS
  • NCATS NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • Institute for Clinical and Translational Research
  • University of Maryland, Baltimore
  • General Clinical Research Center, University of Maryland
  • NIH

Zitieren

APA

Chen, W. H., Barry, E. M., Toapanta, F. R., Pasetti, M. F., Sztein, M. B., Permala-Booth, J., Tennant, S. M., Ortiz, J. R., Thomas, C., McGilvray, M., Roane, L., Datar, R., Liang, Y., & Levine, M. M. (2026). Evaluation of the Safety, Genetic Stability, and Immunogenicity of an Attenuated Shigella Live Vector Expressing Enterotoxigenic Escherichia coli Antigens, Vaccine Strain CVD 1208S-122. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag220

Vancouver

Chen WH, Barry EM, Toapanta FR, Pasetti MF, Sztein MB, Permala-Booth J, et al. Evaluation of the Safety, Genetic Stability, and Immunogenicity of an Attenuated Shigella Live Vector Expressing Enterotoxigenic Escherichia coli Antigens, Vaccine Strain CVD 1208S-122. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag220

BibTeX
@article{Chen2026,
  author = {Chen, Wilbur H and Barry, Eileen M and Toapanta, Franklin R and Pasetti, Marcela F and Sztein, Marcelo B and Permala-Booth, Jasnehta and Tennant, Sharon M and Ortiz, Justin R and Thomas, Constance and McGilvray, Megan and Roane, Lynnee and Datar, Reva and Liang, Yuanyuan and Levine, Myron M},
  title = {Evaluation of the Safety, Genetic Stability, and Immunogenicity of an Attenuated Shigella Live Vector Expressing Enterotoxigenic Escherichia coli Antigens, Vaccine Strain CVD 1208S-122},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  doi = {10.1093/infdis/jiag220}
}
Kostenlos starten →